CPS Technology Platform

Aptar Digital Health is a global leader in end-to-end digital solutions that enhance patient experiences. We combine our unmatched expertise with a diverse, industry-leading portfolio of products and platforms. Our holistic ecosystem includes mobile and web applications, sensors and wearables, and connecte...

Aptar Pharma's Bidose (BDS) is a two-shot, user-friendly nasal delivery device for liquid drugs. This sturdy, self-priming system permits accurate, one-handed operation, enabling non-invasive, systemic drug delivery without the assistance of a healthcare professional.

Aptar Pharma's BAI is a user-friendly, breath-activated pMDI, that enhances adherence across all patient types, including children and the elderly. Suitable even for those with low inspiration rates, it ensures consistent dosage by delivering each dose upon inhalation at the mouthpiece.

Aptar Pharma offers nasal vaccine solutions, suitable for liquid and powder formulations, that ensure precise dosing and ease of use for healthcare professionals. These non-injectable alternatives potentially decrease cold chain storage needs, enhancing distribution.

Aptar Pharma's PremiumCoat(R) offers state-of-the-art ETFE-coated stoppers and plungers, combining superior container closure integrity and compatibility. With its highest standard specifications, it ensures optimal particulate protection for sensitive drugs.

Aptar Pharma's Unidose systems are nasal drug delivery devices for both liquid and powder forms, enabling precise single-dose delivery without healthcare professional intervention.

Aptar Pharma's Prohaler® is a patient-centric, high-performance DPI that ensures optimal patient compliance in treating asthma, COPD, and other pulmonary conditions.

Aptar Pharma’s DF30 metering valve platform is the industry standard for safe and precise medication delivery to patients with life-threatening pulmonary diseases. It is also the benchmark for hydrofluoralkane (HFA) propellant pMDIs. As the pharmaceutical industry shifts towards environmentally friendl...

Aptar CSP's Activ-Vial™ portfolio offers 3-Phase Activ-Polymer™ flip-top vials and bottles in various sizes, providing superior protection for product stability and extended shelf life.

Aptar CSP Technologies' Activ-Film™ material optimizes product stability through imperceptible enhancements for consumers and increased efficiency for manufacturers.

Aptar Pharma's Landmark® dose counting device is FDA compliant and compatible with all pMDIs, including nasal actuators. 

The Advanced Preservative Free (APF) and APF + pumps are innovative, metal-free dispensing systems for nasal and topical use, providing robust microbiological protection for sensitive formulations. The highly recyclable, all-plastic APF Futurity™ system marks a breakthrough in multidose nasal spray tec...

Aptar Pharma's presentation entitled "Innovations in Inhalation" explores the current extensive portfolio of high-quality OINDP (Orally Inhaled and Nasal Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. A key focus of the talk is the introduction of Orbital, an innovative high payload DPI system designed to enhance drug delivery efficiency and patient compliance. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems.

Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product

Aptar Pharma Brochure